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Abstract: 
Many N,N-dialkylated tryptamines show psychoactive properties in humans 
and the number of derivatives involved in multidisciplinary areas of 
research has grown over the last few decades. Whereas some derivatives 
form the basis of a range of medicinal products, others are predominantly 
encountered as recreational drugs, and in some cases, the areas of 
therapeutic and recreational use can overlap. In recent years, 5-methoxy-
N,N-diallyltryptamine (5-MeO-DALT) has appeared as a new psychoactive 
substance (NPS) and ‘research chemical’ whereas 4-acetoxy-DALT and the 
ring-unsubstituted DALT have only been detected very recently. Strategies 
pursued in the authors’ laboratories included the preparation and biological 
evaluation of previously unreported N,N-diallyltryptamines (DALTs). This 
report describes the analytical characterization of seventeen DALTs. Fifteen 
DALTs were prepared by a microwave-accelerated Speeter and Anthony 
procedure following established procedures developed previously in the 
authors’ laboratories. In addition to DALT, the substances included in this 
study were 2-phenyl-, 4-acetoxy-, 4-hydroxy-, 4,5-ethylenedioxy-, 5-
methyl-, 5-methoxy-, 5-methoxy-2-methyl-, 5-ethoxy-, 5-fluoro-, 5-fluoro-
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2-methyl-, 5-chloro-, 5-bromo-, 5,6-methylenedioxy-, 6-fluoro-, 7-methyl, 
and 7-ethyl-DALT, respectively. The DALTs were characterized by nuclear 
magnetic resonance spectroscopy (NMR), gas chromatography (GC) 
quadrupole and ion trap (EI/CI) mass spectrometry (MS), nominal and high 
mass accuracy MS/MS, ultraviolet diode array detection and GC solid-state 
infrared analysis, respectively. A comprehensive collection of spectral data 
was obtained that are provided to research communities who face the 
challenge of encountering newly emerging substances where analytical 
data are not available. These data are also relevant to researchers who 
might wish to explore the clinical and non-clinical uses of these substances. 
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Abstract 
Many N,N-dialkylated tryptamines show psychoactive properties in humans and the 
number of derivatives involved in multidisciplinary areas of research has grown over 
the last few decades. Whereas some derivatives form the basis of a range of 
medicinal products, others are predominantly encountered as recreational drugs, and 
in some cases, the areas of therapeutic and recreational use can overlap. In recent 
years, 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT) has appeared as a new 
psychoactive substance (NPS) and ‘research chemical’ whereas 4-acetoxy-DALT 
and the ring-unsubstituted DALT have only been detected very recently. Strategies 
pursued in the authors’ laboratories included the preparation and biological 
evaluation of previously unreported N,N-diallyltryptamines (DALTs). This report 
describes the analytical characterization of seventeen DALTs. Fifteen DALTs were 
prepared by a microwave-accelerated Speeter and Anthony procedure following 
established procedures developed previously in the authors’ laboratories. In addition 
to DALT, the substances included in this study were 2-phenyl-, 4-acetoxy-, 4-
hydroxy-, 4,5-ethylenedioxy-, 5-methyl-, 5-methoxy-, 5-methoxy-2-methyl-, 5-ethoxy-, 
5-fluoro-, 5-fluoro-2-methyl-, 5-chloro-, 5-bromo-, 5,6-methylenedioxy-, 6-fluoro-, 7-
methyl, and 7-ethyl-DALT, respectively. The DALTs were characterized by nuclear 
magnetic resonance spectroscopy (NMR), gas chromatography (GC) quadrupole 
and ion trap (EI/CI) mass spectrometry (MS), low and high mass accuracy MS/MS, 
ultraviolet diode array detection and GC solid-state infrared analysis, respectively. A 
comprehensive collection of spectral data was obtained that are provided to research 
communities who face the challenge of encountering newly emerging substances 
where analytical data are not available. These data are also relevant to researchers 
who might wish to explore the clinical and non-clinical uses of these substances.  
Introduction 
Many N,N-dialkylated tryptamine derivatives show psychoactive properties in 
humans.[1-5] Naturally occurring N,N-dimethyltryptamines, such as psilocybin, have 
been used for religious purposes since antiquity. Recently, N,N-dialkyltryptamines 
have also been the focus of attention due to increasing research efforts in clinically 
important areas [6-10] including potential treatment options for cluster headaches.[11-14] 
Non-medical and recreational use of both synthetic and naturally occurring 
derivatives and occurrences of untoward effects have been also been observed in 
recent years.[15,16]  
One of the many potential and yet less explored substitution patterns is the synthetic 
N,N-diallyl substituted tryptamine template. The synthesis of the ring-unsubstituted 
tryptamine derivative N,N-diallyltryptamine (DALT) (1) (Figure 1) was first published 
in 1959[17] and indications about its psychoactive properties emerged in 1962, when it 
was briefly noted by Szára and Hearst.[18] In the following years, Szára mentioned a 
‘psychotropic dose’ of 60 mg.[19] Subsequently, Alexander T. Shulgin synthesized 
both DALT (1) and 5-MeO-DALT (7) (A.T. Shulgin, personal communication). 
Although DALT (1) appeared to have few distinct effects at oral doses up to 42 mg[20] 
(80 mg has also been noted elsewhere[21,22]), 5-MeO-DALT (7) was found to produce 
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short-lived, psychoactive effects at a dosage range of 12-20 mg. Remarkably, oral 
administration led to a comparatively fast onset of effects. Some of the information 
shared by Shulgin and Shulgin appeared on various Internet sites in 2004, which 
coincided with the marketing of 5-MeO-DALT (7) by chemical suppliers, presumably 
in response to data shared by Shulgin and Shulgin.[20,23-27] Reports linked to the 
detection of 5-MeO-DALT (7) began to surface in 2007[28-31] and continued to emerge 
until the present day. In recent years, 5-MeO-DALT (7) has been frequently 
discussed within the context of being a new psychoactive substance (NPS) where 
many of these substances are advertised as ‘research chemicals’ and available for 
purchase from Internet retailers or shops.[32,33] As far as the availability of analytical 
data are concerned, the majority of available reports describing the detection and 
characterization DALT derivatives focus on 5-MeO-DALT (7), reflecting its 
appearance in forensically related casework and/or from retail purchases[17,20,27,31,34-61] 
(Table 1).  
 
Strategies pursued in the authors’ laboratories include the preparation of previously 
unreported DALT analogs in order to make available the analytical data to 
researchers who encounter these types of new psychoactive substances (NPS) and 
‘research chemicals’. Furthermore, the psychoactive properties associated with a 
range of N,N-dialkylated tryptamines make the DALT compounds a desirable target 
for pharmacological and pharmacokinetic investigations as reported recently for 
some of the compounds characterized in the present study.[59,61-63] In addition to 5-
MeO-DALT (7),[30] the two additional DALT analogs 4-AcO-DALT (3)[64] and DALT 
(1),[65] also described in the present study, have been detected by the European 
Early-Warning System and reported to the European Monitoring Centre for Drugs 
and Drug Addiction (EMCCDA), which suggested that the development of new DALT 
analogs might be a likely prospect within the ‘research chemical’ context.   
 
Research communities confronted with the NPS phenomenon face a number of 
challenges, which include the lack of analytical data when dealing with newly 
emerging substances. The present study addresses the need for providing a 
comprehensive collection of analytical data for DALT analogs (1) – (17) (Figure 1). 
The majority of spectral data described in this report are described for the first time. 
Synthesized compounds were characterized by nuclear magnetic resonance 
spectroscopy (NMR), gas chromatography (GC) quadrupole and ion trap (EI/CI) 
mass spectrometry (MS), and low and high mass accuracy MS/MS, ultraviolet diode 
array detection and GC solid-state infrared analysis, respectively.  
 
Experimental 
 
Materials 
 
4-AcO-DALT (3) and 4-OH-DALT (4), sold as the fumarate salt, were from Scientific 
Supplies (London, UK). 5-MeO-2-Me-DALT HCl (8) and 5-EtO-DALT HCl (9) were 
available from previous studies.[39,42]  
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The synthesis of N,N-diallyltryptamines (DALTs) reported in this study adopted the 
well-established procedure of Speeter and Anthony.[66] As summarized in the 
Supporting Information, the substituted indole starting material (a) was acylated to 
give the acid chloride intermediate (b) followed by amination with N,N-diallylamine to 
the yield glyoxalylamide (c). The reduction with lithium aluminum hydride provided 
the DALT analogs. The reduction of the corresponding glyoxalylamide (c) (0.3 mmol) 
was carried out under microwave-accelerated conditions as described in detail by the 
authors previously.[35,39,42] High accuracy electrospray ionization mass spectra of the 
protonated molecules and their key product ions are summarized in Table 3. All 1H 
and 13C NMR data for intermediates (c) and DALTs (1) – (17) are presented as 
Supporting Information. 
 
Instrumentation 
 
Gas chromatography-mass spectrometry (GC-MS) 
 
Electron ionization (EI) mass spectra (70 eV) were recorded using a Finnigan TSQ 
7000 triple stage quadrupole mass spectrometer coupled to a gas chromatograph 
(Trace GC Ultra, Thermo Electron) using a CTC CombiPAL (CTC Analytics, 
Switzerland) autosampler. The emission current was 200 µA and the scan time was 
1 s spanning a scan range between m/z 29 – m/z 600. The ion source temperature 
was maintained at 175 °C. Samples were introduced via GC with splitless injection 
using a fused silica capillary DB-1 column (30 m x 0.25 mm, film thickness 0.25 µm). 
The temperature program consisted of an initial temperature of 80 °C, held for 1 min, 
followed by a ramp to 280 °C at 15 °C/min. The final temperature was held for 21 
min. The injector temperature was 220 °C. The transfer line temperature was 
maintained at 280 °C and the carrier gas was helium in constant flow mode at a flow 
rate of 1.0 mL/min. Approximately 2 mg were dissolved in 1.5 mL methanol. For 
analysis, 1 µL sample solutions were injected into the GC-MS system.  
 
Gas chromatography solid-state infrared analysis (GC-sIR) 
 
The methanolic solution was measured on a GC-solid phase-IR-system consisting of 
an Agilent GC 7890B (Waldbronn, Germany) with probe sampler Agilent G4567A 
and a DiscovIR-GC™ (Spectra Analysis, Marlborough, Massachusetts, USA). The 
column eluent was cryogenically accumulated on a rotating ZnSe disk that was 
cooled by liquid nitrogen. The IR spectra were directly recorded through the IR-
transparent ZnSe disk using a nitrogen cooled MCT detector. GC parameters: the 
injection was carried out in splitless mode with an injection port temperature of 
240 °C and a DB-1 fused silica capillary column (30 m x 0.32 mm i.d., 0.25 µm film 
thickness). The carrier gas was helium with a flow rate of 2.5 mL/min; oven 
temperature program: 80 °C for 2 min, ramped to 290 °C at 20 °C/min, and held at 
the final temperature for 25 min. The transfer line heater was set at 280 °C. IR 
conditions: oven temperature, restrictor temperature, disc temperature, and Dewar 
cap temperatures were 280 °C, 280°C, −40 °C, and 35 °C, respectively. The vacuum 
was 0.2 mTorr, disc speed 3 mm/s, spiral separation was 1 mm, wavelength 
resolution 4 cm-1 and IR range 650–4000 cm-1. Acquisition time was 6s/file with 64 
scans/spectrum. Data were processed using GRAMS/AI Ver. 9.1 (Grams 
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Spectroscopy Software Suite, Thermo Fischer Scientific) followed by implementation 
of the OMNIC Software, Ver. 7.4.127 (Thermo Electron Corporation). 
High-resolution electrospray ionization mass spectrometry (HR-ESI-MS) 
High-resolution mass spectral and MS/MS analyses were performed on an 
LTQ/Orbitrap™ Discovery mass spectrometer (Thermo Scientific, Bremen, 
Germany). This hybrid system consists of a linear ion trap (LTQ™) coupled to an 
Orbitrap™ Fourier transform mass spectrometer for accurate mass measurements. 
Samples were dissolved in acetonitrile/water (1:1, containing 0.1% formic acid) and 
infused at a rate of 5 µL/min. Measured accurate masses were within ± 5 ppm of the 
theoretical masses. The following conditions were used: drying gas (N2) 10 L/min, 
capillary temperature 310 °C, spray voltage 4 V, capillary voltage, 22 V and tube lens 
77 V. A normalized collision energy™ (NCE) of 45% (of a maximum of 5 eV) was 
used for CID. Full scan high-resolution (30,000 FWHM) spectra (m/z 75 – 400) were 
acquired in positive electrospray ionization (ESI) mode. Mass calibrations were 
performed using solutions of caffeine, L-methionyl-arginyl-phenylalanylalanine 
acetate × H20 (MRFA), Ultramark 1621
®, sodium docecyl sulfate and sodium
taurocholate. 
Diode array detection (DAD) 
HPLC-DAD analyses were performed on an Agilent 1200 HPLC system equipped 
with the following modules: G1312B BinPump SL, G13798 degasser, G1367D HiP 
ALS SL plus autosampler, a G1316B column compartment (set at 35 °C), and a 
G1315C diode array detector (Agilent, Waldbronn, Germany). Data acquisition rate 
was 80 Hz with the scan rate set between 210 – 400 nm (spectrum step 1 nm).  The 
injection volume was 10 µL (0.1 mg/mL analyte solution). A Synergi Max-RP (250 x 
4.6 mm, 4 µm) column from Phenomenex (Macclesfield, United Kingdom) was used 
and analytes were eluted under gradient conditions. Mobile phase A consisted of 25 
mM triethylammonium phosphate (TEAP) buffer solution and mobile phase B 
comprised of 70% acetonitrile and 30% water containing 25 mM TEAP. The gradient 
elution commenced at 70% A and decreased to 5% within 5 min. This was then held 
until 12 min and returned to initial conditions by a 5 min post time.  
Liquid chromatography-mass spectrometry (LC-MS) 
LC-MS analyses were performed on an Agilent 1100 HPLC system equipped with a 
G13795 degasser, G1312A BinPump, a G1313A ALS and G1316A column oven 
(COLCOM) (Agilent, Little Island, Cork, Ireland). Separation was obtained on a 
Kinetex phenyl-hexyl column (2.6 µm, 100 x 2.10 mm) Phenomenex (Macclesfield, 
Cheshire, United Kingdom). The analytes were eluted under isocratic conditions 
using amobile phase of 97%water and 3%acetonitrile (both containing 0.1% formic 
acid). The Agilent single quadrupole MSD settings were as follows: positive 
electrospray mode, capillary voltage 3500 V, drying gas (N2) 12 L/min at 350 °C, and 
nebulizer gas (N2) pressure 50 psi. In-source collision-induced dissociation 
experiments were carried out with an increased fragmentor voltage of 110 V. 
Samples were dissolved in acetonitrile/water (1:1, containing 0.1% formic acid) at a 
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concentration of 10 µg/mL. The injection volume was 0.5 µL, flow rate was 0.4 
mL/min and the column temperature was set at 30 °C. Total run time was 25 min. 
Results and discussion 
Electron ionization (EI) quadrupole mass spectra recorded for DALTs (1) – (17) 
featured a fragmentation behavior similar to other N,N-dialkyltryptamines[67,68] and a 
generalized scheme is proposed in Figure 2 to encompass the key features. The 
associated main fragments are summarized in Table 2 and all EI quadrupole mass 
spectra are provided as Supporting Information. Consistent with previously published 
reports about 5-MeO-DALT (7) and some of the other DALT analogs (Table 1), base 
peak formation of the iminium ion was observed at m/z 110 via alpha-cleavage 
(Figure 2A, pathway ‘a’). The allyl ion at m/z 41 was also frequently observed, 
possibly formed by secondary fragmentation of m/z 110 or directly from the ionized 
allyl double bond in the intact molecular ion. An [M – 41]+ species, albeit occasionally 
low in relative abundance, is proposed to fragment further into [C10H8NR’R’’]
+ and
[C8H4NR’R’’]
+, respectively (Figure 2A, pathway ‘b’). Formation of [C10H7NR’R’’]
+ and
[C8H3NR’R’’]
+ ions might have followed the proposed mechanism shown in Figure 2B
whereas detection of [C9H6NR’R’’]
+ might have resulted from alpha-cleavage
instigated from ionization of C2 – C3 double bond of the indole ring (Figure 2C). 
Implementation of GC ion trap mass spectrometry showed some variations, for 
example, in relative abundance of fragment ions when compared those formed under 
quadrupole mass spectrometry conditions, which might have reflected the tendency 
to display self-ionization phenomena within the ion trap. For completeness, GC ion 
trap MS (GC-IT-MS) data using both EI and chemical ionization methods have been 
included as Supporting Information. Interestingly, an ion at m/z 228 was observed in 
the EI mass spectrum of MD-DALT (14) (Table 2, Figure 3A) and it was speculated 
that the associated loss of 56 amu from the molecular ion might have arisen from 
mechanisms proposed in Figure 3B and 3C. In the first scenario, MD-DALT (14) 
would have been required to degrade into an ortho-benzoquinone derivative before 
being subjected to a neutral loss off propene (Figure 3B). An alternative pathway 
might have involved an H-shift and rearrangement, possibly including an epoxide and 
benzoquinone intermediate. A subsequent loss of a methyl radical followed by a loss 
of an allyl radical could have accounted for m/z 228 (Figure 3C).   
One of the challenges that might be encountered when identifying a new 
psychoactive substance on the market includes the consideration of potential 
isomers,[69,70] especially if not all of these substances are commercially available for 
analytical comparisons. From this perspective, it has become increasingly helpful to 
consider supporting implementation of analytical procedures by synthesis of the 
isomers of interest to support the verification process.[71-74] Figure 4 shows the 
similarity of EI mass spectra recorded for 5-F-DALT (10) and 6-F-DALT (15). As 
expected, these similarities precluded unambiguous identification and although the 
GC retention index values were slightly dissimilar under the conditions used but not 
sufficient for unambiguous identification without having both standards (see also 
supplemental GC-IT-MS data). An inspection of the photodiode array spectra 
obtained for both substances revealed only minor differences of potential 
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significance, such as distinct shoulders at lower wavelengths between 200 nm and 
230 nm (Figure 5A). The photo diode array spectra (PDA) of all DALTs are given as 
Supporting Information. The recorded PDA spectrum of 5-MeO-DALT (7) was 
consistent with one reported in the literature.[31]  
The most promising data was obtained from GC solid-state infrared analysis (GC-
sIR) as shown in Figure 5B – 5E. The expanded spectral regions shown in Figure 5C 
(5-F-DALT (10)) and Figure 4E (6-F-DALT (15)) confirmed that distinct differences 
could be noted between the two positional isomers. In case of 6-F-DALT (15), the 
more prominent differences included the sharp signals at wavenumbers 1630.0, 
1460.7 1348.2, 1150.3 and 802.2 cm-1, respectively. The advantage of employing a 
GC-sIR procedure was the formation of solid and amorphous free base material 
following elution of the analyte from the GC column. Consequently, IR spectra 
obtained from this procedure are comparable to standard spectra of the free bases 
recorded from attenuated total reflectance IR devices and are especially useful in 
identification of the correct isomers in analysis of mixtures. The GC-sIR spectra of all 
DALTs (1) – (17) are provided as Supplementary Information.  
Positive electrospray (ES+) high-resolution MS and MS/MS data for all DALTs are 
summarized in Table 3 and, consistent with literature reported previously (Table 1), 
two key product ions were detected. The detected product ions were comparable to 
those observed when exposing the DALTs to analysis by LC positive mode single 
quadrupole mass spectrometry and in-source collision-induced dissociation. All mass 
spectra have been provided as Supporting Information.  
The present study provided a comprehensive set of spectral data obtained from 
seventeen N,N-diallyltryptamines (DALTs) in order to facilitate the identification and 
exploration of these newly emerging substances. Another challenge frequently 
encountered with new psychoactive substances is the lack of information regarding 
their biological properties, which triggered a first set of studies carried out in the 
authors’ laboratories in the areas of metabolism[59] and cytochrome P450 inhibition.[61] 
Receptor binding data for 5-MeO-DALT (7)[45] and additional DALTs substituted at 
the 5-position have also appeared recently.[63] The fact that a range of closely related 
N,N-dialkylated tryptamines (e.g. sumatriptan) show important therapeutic 
applications demonstrates that there is a need to disentangle the different 
pharmacological features associated with the tryptamine template. [5,75-81] Anecdotal 
reports suggest that 5-MeO-DALT (7) might provide relief from cluster headaches.[82] 
However, the extent to which this might apply to this particular compound or other 
DALTs warrants further investigation.   
Conclusion 
The new psychoactive substances phenomenon is an area of investigation that 
attracts attention from multi-disciplinary stakeholders who face the challenge of 
keeping up-to-date with newly emerging substances where few data are available 
that aid their identification. The characterization of seventeen N,N-diallyltryptamines 
yielded a comprehensive set of analytical data that were collected to serve these 
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research communities that are involved with the study of psychoactive substances 
including both clinical and non-clinical applications. 
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Figure captions: 
 
Figure 1.  Structures of ring-substituted N,N-diallyltryptamines (1) – (17)  
characterized in this study. 
 
Figure 2.  Proposed, generalized mass spectral fragm ntation pathways for (1) – 
(17) recorded under electron ionization conditions (see also Table 2).  
 
Figure 3.  A: Electron ionization mass spectrum recorded for MD-DALT (14).  B and 
C: Two proposed alternative mass spectral fragmentation pathways that may 
account for the formation of m/z 228.  
 
Figure 4.  Electron ionization mass spectra recorded for the two isomers 5-F-DALT 
(10) and 6-F-DALT (15).  
 
Figure 5.  A. Implementation of photodiode array detection for both isomers 5-F-
DALT (10) and 6-F-DALT (15). B and C: Gas chromatography solid-state infrared 
data recorded for (10). D and E: Gas chromatography solid-state infrared data 
recorded for (15). Isomers (10) and (15) could be differentiated due to differences 
observed in the partial spectra C and E. 
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Table 1. Reports that describe the analysis of N,N-diallyltryptamines 
Compound 
a
Techniques 
b
Comment Ref. 
DALT (1) Elemental analysis Synthesis employing 3-(2-bromoethyl)indole and N,N-diallylamine 
[17]
DALT (1) GC-MS, IR Synthesis employing N,N-dialkylation of tryptamine 
[20]
5-MeO-DALT (7) GC-MS, IR Synthesis employing N,N-dialkylation of 5-methoxytryptamine  
[27]
5-MeO-DALT (7) GC-MS, LC-MS, LC-PDA Analytical characterization 
[31]
5-MeO-DALT (7) 
c
GC-MS, IR, 
1
H NMR 
c
Synthesis employing N,N-dialkylation of 5-methoxytryptamine 
c [34]
d4-DALT (1) 
d4-5-MeO-DALT (7) 
1
H and 
13
C NMR Synthesis of deuterated standards via microwave-accelerated Speeter and 
Anthony procedure 
[35]
5-MeO-DALT (7) GC-MS, LC-PDA Five out of 29 tryptamine products purchased between April 2005 and March 
2008 were found to contain 5-MeO-DALT (7).  
[36]
5-MeO-DALT (7) LC-MECD Analytical characterization 
[37]
5-MeO-DALT (7) 
c
LC-MS 
c
Analytical characterization 
c [38]
5-EtO-DALT (9) 
d4-5-EtO-DALT (9) 
GC-EI-IT-MS, GC-CI-IT-
MS/MS, 
1
H and 
13
C NMR
Synthesis via microwave-accelerated Speeter and Anthony procedure 
[39]
5-MeO-DALT (7) 
c
LC-MS, LC-PDA 
c
Analytical characterization 
c [40]
DALT (1) LC-UV, 
1
H and 
13
C NMR, IR Synthesis employing 3-(2-bromoethyl)indole and N,N-diallylamine 
[41]
5-MeO-2-Me-DALT (8) GC-EI-IT-MS, GC-CI-IT-
MS/MS, 
1
H and 
13
C NMR
Synthesis via microwave-accelerated Speeter and Anthony procedure 
[42]
5-MeO-DALT (7) LC-DAD, LC-MS Detection in postmortem femoral blood 
[43]
5-MeO-DALT (7) 
d
-- 
d
Synthesis employing N,N-dialkylation of 5-methoxytryptamine 
d [44]
5-MeO-DALT (7) 
1
H and 
13
C NMR, UV, IR Analytical characterization and receptor binding assays 
[45]
5-MeO-DALT (7) GC-MS, LC-MS, NMR, DART-
TOF-MS 
Liquid (n = 111) and powdered (n = 13) products purchased via the Internet 
between September 2009 and February 2012. Tryptamines including 5-MeO-
DALT (7) detected in 31% of the samples. 
[46]
5-MeO-DALT (7) GC-MS Detection in herbal mixture also containing phenazepam and two synthetic 
cannabinoids 
[47]
5-MeO-DALT (7) Presumptive color test No reaction observed with sodium 1,2-naphthoquinone-4-sulphonate (NQS) 
[48]
5-MeO-DALT (7) SRI-ToF-MS Compounds derived from test purchases 
[49]
5-MeO-DALT (7) GC-MS Detection in herbal products (8 out of 75) containing synthetic cannabinoids 
[50]
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 2 
collected between 2011 and June 2013.  
5-MeO-DALT (7) LC-DAD, LC-MS/MS, LC-
QTOF-MS/MS 
One detection in casework in 2010 
[51]
 
5-MeO-DALT (7) Not reported Case report featuring acute toxicity; no analytical confirmation 
[52]
 
DALT (1) 
2-Ph-DALT (2) 
5-Me-DALT (6) 
5-MeO-DALT (7) 
5-MeO-2-Me-DALT (8) 
5-EtO-DALT (9) 
d4-5-EtO-DALT (9) 
MD-DALT (14) 
7-Me-DALT (16) 
7-Et-DALT (17) 
5-BnO-DALT 
e
 
LC-LIT-MS Method development and detection in human urine and plasma 
[53]
 
5-MeO-DALT (7) 
5-MeO-DALT-TMS 
f
 
GC-MS, LC-QqQ-MS, 
1
H NMR Synthesis employing N,N-dialkylation of 5-methoxytryptamine and 
characterization. 
[54]
 
5-MeO-DALT (7) LC-CLND Analysis of seized samples collected between 2011 – 2013.  
[55]
 
5-MeO-DALT (7) LC-DAD, LC-MS/MS, LC-
QTOF-MS/MS 
5-MeO-DALT (7) remained stable for over 21 days in both blood and plasma 
stored at room temperature  
[56]
 
5-MeO-DALT (7) GC-MS, LC-HR-MS Detection in a seized sample 
[57]
 
5-MeO-DALT (7) Portable NIR Presumptive testing and application to forensic samples 
[58]
 
DALT (1) 
d4-DALT (1) 
5-MeO-DALT (7) 
GC-MS, LC-HR-MS, LC-LIT-
MS 
Identification of phase I and II metabolites in rat urine and in pooled human 
liver microsomes and initial CYP activity screening 
[59]
 
5-MeO-DALT (7) DLLME, LC-MS/MS Detection in spiked blood samples 
[60]
 
DALT (1) 
ED-DALT (5) 
5-Me-DALT (6) 
5-MeO-DALT (7) 
LC-HR-MS, LC-QqQ-MS/MS Cytochrome P450 inhibition assays and determination of in vivo CYP1A2 
inhibition by 5-MeO-DALT (7) (caffeine as test substrate) 
 
 
[61]
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3 
5-F-DALT (10) 
5-F-2-Me-DALT (11) 
5-Cl-DALT (12) 
5-Br-DALT (13) 
MD-DALT (14) 
6-F-DALT (15) 
7-Me-DALT (16) 
a
 Substances other than 5-MeO-DALT (7) have also been studied in a number of references cited in this table. 
b
 GC-MS: gas chromatography mass spectrometry: IR: infrared spectroscopy; NMR: nuclear magnetic resonance spectroscopy; LC: various 
forms of high performance liquid chromatography; PDA: photo diode array detection; MECD: multi-channel electrochemical detection; GC-EI-IT-
MS: GC electron ionization ion trap mass spectrometry; GC-CI-IT-MS/MS: GC chemical ionization ion trap tandem mass spectrometry; UV: 
ultraviolet spectroscopy; DART: direct analysis in real tim ; TOF: time-of-flight; SRI: selective reagent ionization; QTOF: quadrupole time-of-flight; 
HR-MS: high-resolution MS; LIT: linear ion trap; QqQ: triple quadrupole; CLND: chemiluminescence nitrogen detection; NIR: near infrared 
spectroscopy; DLLME: dispersive liquid/liquid microextraction.  
c
Reference in abstract form [written in Japanese] via SciFinder
®
.
d
 Patent source written in Chinese. 
e
 5-BnO-DALT: 5-benzyloxy-DALT; not included in the present study. 
f
 TMS: Trimethylsilyl derivative. 
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Table 2. Electron ionization mass spectral data 
 
No. R' R'' M
+
 [M-41]
+
 [C9H6NR'R'']
+
 [C10H8NR'R'']
+
, 
[C10H7NR'R'']
+ 
[C8H4NR'R'']
+
, 
[C8H3NR'R'']
+ 
Other fragments 
1 H H 240 199 130 144, 143 116, 115 -- 
2 H Ph 316 275 206 220, 219 192, 191 -- 
3 4-AcO H 298 257 188 202, 201 174, 173 256 (M - C2H2O), 239 (M - 
OAc), 
160 (188 - CO), 146 (188 - C2H2O) 
4 4-OH H 256 215 146 160, 159 132, 131 -- 
5 4,5-ED 
a
 H 298 257 188 202, 201 176, 175 160 (188 - C2H4), 132 (160 - CO) 
6 5-CH3 H 254 213 144 158, 157 130, 129 -- 
7 5-OCH3 H 270 239 160 174, 173 146, 145 239 (M - 
OCH3), 145 (160 - 
CH3),  
240 (M - CH2O), 130 (160 - CH2O), 117 
(145 - CO) 
8 5-OCH3 CH3 284 243 174 188, 187 160, 159 253 (M - 
OCH3), 159 (174 - 
CH3), 144 
(174 - CH2O), 131 (159 - CO) 
9 5-OC2H5 H 284 241 174 188, 187 160, 159 269 (M - 
CH3), 239 (M - C2H5O
),  
146 (174 - C2H4) 
10 5-F H 258 217 148 162, 161 134, 133 -- 
11 5-F CH3 272 231 162 176, 175 148, 147 -- 
12 5-Cl H 274/276 233/235 164/166 178/180, 177/179 150/152, 149/147 239 (M - Cl) 
13 5-Br H 318/320 277/279 208/210 222/220, 221/223 194/192, 193/191 239 (M - Br) 
14 5,6-MD
 b
 H 284 243 174 188, 187 160, 159 228, 144 (174 - CH2O) 
15 6-F H 258 217 148 162, 161 134, 133 -- 
16 7-CH3 H 254 213 144 158, 157 130, 129 -- 
17 7-C2H5 H 268 227 158 172, 171 144, 143 239 (M - C2H5
) 
a 
4,5-(OCH2CH2O): 4,5-ethylenedioxy; 
b 
5,6-(OCH2O): 5,6-methylenedioxy. 
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Table 3. Positive electrospray high-resolution MS and MS/MS data 
 
  
 
 
[M+H]
+
  
 
 
(C7H12N
+
) 
(Theor. 110.09643) 
No. R R’ Formula Theor. Found ∆ (ppm) Formula Theor. Found ∆ (ppm) Found ∆ (ppm) 
1 H H C16H21N2
+
 241.16993 241.16978 -0.58 C10H10N
+
 144.08078 144.08072 -0.39 110.09638 -0.40 
2 H Ph C22H25N2
+
 317.20123 − − C16H14N
+
 220.11208 220.11179 -1.32 110.09634 -0.81 
3 4-AcO H C18H23N2O2
+
 299.17540 229.17523 -0.58 C12H12NO2
+
 202.08626 202.08627 0.09 110.09646 0.29 
4 4-OH H C16H21N2O
+
 257.16484 257.16479 -0.17 C10H10NO
+
 160.07569 160.07588 1.20 110.09648 0.50 
5 4,5-ED 
a
 H C18H23N2O2
+
 299.17540 299.17459 -2.72 C12H12NO2
+
 202.08626 202.08606 -0.97 110.09640 -0.26 
6 5-CH3 H C17H23N2
+
 255.18558 255.18533 -0.95 C11H12N2
+
 158.09643 158.09634 -0.52 110.09637 -0.54 
7 5-OCH3 H C17H23N2O
+
 271.18049 271.17999 -1.83 C11H12NO
+
 174.09134 174.09113 -1.24 110.09633 -0.88 
8 5-OCH3 CH3 C18H25N2O
+
 285.19614 285.19565 -1.72 C12H14NO
+
 188.10699 188.10666 -1.76 110.09628 -1.30 
9 5-OC2H5 H C18H25N2O
+
 285.19614 285.19574 -1.40 C12H14NO
+
 188.10699 188.10678 -1.11 110.09631 -1.09 
10 5-F H C16H20FN2
+
 259.16050 259.16010 -1.57 C10H9FN
+
 162.07135 162.07117 -1.15 110.09633 -0.88 
11 5-F CH3 C17H22FN2
+
 273.17615 273.17578 -1.36 C11H11FN
+
 176.08700 176.08679 -1.20 110.09633 -0.88 
12 5-Cl H C16H20
35
ClN2
+ 
C16H20
37
ClN2
+
 
275.13095 
277.12800 
275.13092/ 
277.12759 
-0.12 
-1.48 
C10H9
35
ClN
+ 
-- 
178.04180 
-- 
178.04187 
-- 
0.44 
-- 
110.09645 0.23 
13 5-Br H C16H20
79
BrN2
+ 
C16H20
81
BrN2
+
 
319.08044 
321.07839 
319.07999/ 
321.07779 
-1.41 
-1.87 
C10H9
79
BrN
+ 
-- 
221.99129 
-- 
221.99121 
-- 
-0.35 
-- 
110.09642 -0.05 
14 5,6-MD 
b
 H C17H21N2O2
+
 285.15975 285.15918 -2.02 C11H10NO2
+
 188.07061 188.07062 -0.07 110.09638 -0.40 
15 6-F H C16H20FN2
+
 259.16050 259.16013 -1.46 C10H9FN
+
 162.07135 162.07117 -1.26 110.09628 -1.30 
16 7- CH3 H C17H23N2
+
 255.18558 255.18524 -1.31 C11H12N
+
 158.09643 158.09621 -1.38 110.09631 -1.09 
17 7- C2H5 H C18H25N2
+
 269.20123 269.20068 -2.01 C12H14N
+
 172.11208 172.11194 -0.80 110.09637 -0.47 
a 
4,5-(OCH2CH2O): 4,5-ethylenedioxy; 
b 
5,6-(OCH2O): 5,6-methylenedioxy. 
 
N
H
NH
R'' N
H
R''
[M+H]+
N
H
N
R''
H
[M+H]+
N
R' R' R'
N
H
R''
R'
N
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Figure 1.  Structures of ring-substituted N,N-diallyltryptamines (1) – (17)  characterized in this study. 
120x169mm (300 x 300 DPI)  
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Figure 2.  Proposed, generalized mass spectral fragmentation pathways for (1) – (17) recorded under 
electron ionization conditions (see also Table 2).  
238x295mm (300 x 300 DPI)  
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Figure 3.  A: Electron ionization mass spectrum recorded for MD-DALT (14).  B and C: Two proposed 
alternative mass spectral fragmentation pathways that may account for the formation of m/z 228.  
287x421mm (300 x 300 DPI)  
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Figure 4.  Electron ionization mass spectra recorded for the two isomers 5-F-DALT (10) and 6-F-DALT (15). 
180x218mm (300 x 300 DPI)  
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Figure 5.  A. Implementation of photodiode array detection for both isomers 5-F-DALT (10) and 6-F-DALT 
(15). B and C: Gas chromatography solid-state infrared data recorded for (10). D and E: Gas 
chromatography solid-state infrared data recorded for (15). Isomers (10) and (15) could be differentiated 
due to differences observed in the partial spectra C and E.  
245x291mm (300 x 300 DPI)  
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